Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis Participants of the Delphi Survey are shown in Appendix A .
dc.contributor.author | Distler, Oliver | en_US |
dc.contributor.author | Behrens, Frank | en_US |
dc.contributor.author | Pittrow, David | en_US |
dc.contributor.author | Huscher, Doerte | en_US |
dc.contributor.author | Denton, Christopher P. | en_US |
dc.contributor.author | Foeldvari, Ivan | en_US |
dc.contributor.author | Humbert, Marc | en_US |
dc.contributor.author | Matucci-Cerinic, Marco | en_US |
dc.contributor.author | Nash, Peter | en_US |
dc.contributor.author | Opitz, Christian F. | en_US |
dc.contributor.author | Rubin, Lewis J. | en_US |
dc.contributor.author | Seibold, James R. | en_US |
dc.contributor.author | Furst, Daniel E. | en_US |
dc.date.accessioned | 2008-07-01T14:06:16Z | |
dc.date.available | 2009-07-06T16:34:52Z | en_US |
dc.date.issued | 2008-06-15 | en_US |
dc.identifier.citation | Distler, Oliver; Behrens, Frank; Pittrow, David; Huscher, Doerte; Denton, Christopher P.; Foeldvari, Ivan; Humbert, Marc; Matucci-Cerinic, Marco; Nash, Peter; Opitz, Christian F.; Rubin, Lewis J.; Seibold, James R.; Furst, Daniel E. (2008). "Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis Participants of the Delphi Survey are shown in Appendix A . ." Arthritis & Rheumatism 59(6): 867-875. <http://hdl.handle.net/2027.42/60213> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/60213 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18512721&dopt=citation | en_US |
dc.description.abstract | Objective Outcome measures for pulmonary arterial hypertension associated with systemic sclerosis (PAH-SSc) are only partially validated. The aim of the present study was to establish an expert consensus regarding which outcome measures are most appropriate for clinical trials in PAH-SSc. Methods Sixty-nine PAH-SSc experts (rheumatologists, cardiologists, pulmonologists) rated a list of disease domains and measurement tools in an Internet-based 3-stage Delphi consensus study. In stages 2 and 3, the medians of domains and measurement tools and frequency distributions of ratings, along with requests for re-ratings, were distributed to respondents to provide feedback. A final score of items was identified by means of cluster analysis. Results The experts judged the following domains and tools as most appropriate for randomized controlled trials in PAH-SSc: lung vascular/pulmonary arterial pressure and cardiac function both measured by right heart catheterization and echocardiography, exercise testing measured by 6-minute walking test and oxygen saturation at exercise, severity of dyspnea measured on a visual analog scale, discontinuation of treatment measured by (serious) adverse events, quality of life/activities of daily living measured by the Short Form 36 and Health Assessment Questionnaire disability index, and global state assessed by physician measured by survival. Conclusion Among experts in PAH-SSc, a core set of outcome measures has been defined for clinical trials by Delphi consensus methods. Although these outcome measures are recommended by this expert group to be used as an interim tool, it will be necessary to formally validate the present measures, as well as potential research measures, in further studies. | en_US |
dc.format.extent | 581095 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.title | Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis Participants of the Delphi Survey are shown in Appendix A . | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Scleroderma Program, Ann Arbor | en_US |
dc.contributor.affiliationother | University Hospital Zurich, Zurich, Switzerland ; Dr. Distler has received consultancies and/or speaking fees (less than $10,000 each) from Actelion and Encysive. | en_US |
dc.contributor.affiliationother | J. W. Goethe University, Frankfurt, Germany | en_US |
dc.contributor.affiliationother | Technical University, Dresden, Germany | en_US |
dc.contributor.affiliationother | German Rheumatism Research Centre, Berlin, Germany | en_US |
dc.contributor.affiliationother | Royal Free and University College Medical School, London, UK ; Dr. Denton has received consultancies and honoraria (less than $10,000 each) from Actelion and Encysive. | en_US |
dc.contributor.affiliationother | General Hospital Eilbek, Eilbek, Germany ; Dr. Foeldvari has received consultancies (less than $10,000 each) from Encysive and Roche. | en_US |
dc.contributor.affiliationother | HÔpital Antoine Beclere, Assistance Publique HÔpitaux de Paris, and UniversitÉ Paris-Sud 11, Clamart, France ; Dr. Humbert has received consultancies and honoraria (less than $10,000 each) from Actelion, Bayer Schering, GSK, Novartis, Pfizer, and United Therapeutics. | en_US |
dc.contributor.affiliationother | University of Florence, Florence, Italy ; Dr. Matucci-Cerinic has received consultancies and/or speaking fees (less than $10,000 each) from Actelion, Encysive, Schering Plough, BMS, and Wyeth, and research grants from Actelion, Encysive, and Schering Plough. | en_US |
dc.contributor.affiliationother | University of Queensland, Queensland, Australia ; Dr. Nash has received speaking fees and honoraria (less than $10,000) from Actelion and research grants from Actelion. | en_US |
dc.contributor.affiliationother | DRK-Kliniken Berlin, Westend, Berlin, Germany ; Dr. Opitz has received consultancies and/or honoraria (less than $10,000 each) from Actelion, Encysive, GSK, Pfizer, and Bayer Schering. | en_US |
dc.contributor.affiliationother | University of California, San Diego ; Dr. Rubin has received consultancies (more than $10,000 each) from NHBLI, Actelion, Pfizer, United Therapeutics, Gilead, Aires, Bayer Schering Pharma, MondoBiotech, Novartis, Jerini AG, EPIX Pharmaceuticals, Broncus Technologies, Solvay, Cogentus, and GeneraMedix, investor consultancies from Gerson Lehrman Group, MEDACorp, Guidepoint Global Advisors, Piper Jaffray, and Citigroup, investment research from Vista Research and Concert Pharmaceuticals, research grants from NHBLI, Actelion, MondoBiotech, Gilead, United Therapeutics, Pfizer, and MD Primer, and holds stock in United Therapeutics. | en_US |
dc.contributor.affiliationother | David Geffen School at University of California, Los Angeles ; Division of Rheumatology, Department of Medicine, David Geffen School at UCLA, 1000 Veteran Avenue, Room 32-59, Los Angeles, CA | en_US |
dc.identifier.pmid | 18512721 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/60213/1/23718_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/art.23718 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.